Primary Screening Test for Diabetes Reevaluated
|
By LabMedica International staff writers Posted on 04 Jan 2012 |
|
The blood test for glycosalated hemoglobin, Hb1Ac, has been recently recommended as the primary diagnostic test for diabetes.
The HbA1c blood test is the accepted standard for monitoring long-term glycemic control in patients with diabetes, however until recently, HbA1c was not recommended for diagnosing or screening for diabetes.
In a retrospective study carried out by DynaLIFEDx, Edmonton, AB, Canada) in conjunction with local medical practitioners, evaluated the positive predictive value (PPV) and negative predictive value (NPV) of HbA1c against the oral glucose tolerance test (OGTT) values using a 10% prevalence of diabetes in three locations. DynaLIFEDx is a major Canadian medical laboratory offering a complete range of diagnostic testing services. For a three-year period, 3,163 data pairs were collected including 1,537 males and 1,626 females with a mean age of 55.4 ± 14.7 years. The OGTT criteria for diabetes were found for 568 out of the 3,163 sets.
Blood glucose was measured on the ARCHITECT ci8200 (Abbott Laboratories; Mississauga, ON, Canada) using a hexokinase method and HbA1c was measured by high performance liquid chromatography (HPLC) on a VARIANT II analyzer (Bio-Rad laboratories, Montreal, QC, Canada). The recommended threshold HbA1c value of 6.5% did not give the optimal combination of NPV of 0.93 to 0.92 and PPV of 0.40 to 0.61 compared to a threshold HbA1c value of 7.0% that gave an NPV of 0.91 to 0.92, and PPV of 0.61 to 0.73.
The authors concluded that HbA1c is not satisfactory for use as a diagnostic test for diabetes using the threshold values recommended by the Consensus Committee and the International Expert panel due to low positive predictive values. About 12% of individuals with a normal OGTT test will be diagnosed with diabetes using a threshold HbA1c value of 7.0%. This would put considerable burden on health care resources. However, based on the high negative predictive value, HbA1c may be used as a test to rule-out diabetes. The study was published in the December 2011 issue of the journal Clinical Biochemistry.
Related Links:
DynaLIFEDx
Abbott Laboratories
Bio-Rad
The HbA1c blood test is the accepted standard for monitoring long-term glycemic control in patients with diabetes, however until recently, HbA1c was not recommended for diagnosing or screening for diabetes.
In a retrospective study carried out by DynaLIFEDx, Edmonton, AB, Canada) in conjunction with local medical practitioners, evaluated the positive predictive value (PPV) and negative predictive value (NPV) of HbA1c against the oral glucose tolerance test (OGTT) values using a 10% prevalence of diabetes in three locations. DynaLIFEDx is a major Canadian medical laboratory offering a complete range of diagnostic testing services. For a three-year period, 3,163 data pairs were collected including 1,537 males and 1,626 females with a mean age of 55.4 ± 14.7 years. The OGTT criteria for diabetes were found for 568 out of the 3,163 sets.
Blood glucose was measured on the ARCHITECT ci8200 (Abbott Laboratories; Mississauga, ON, Canada) using a hexokinase method and HbA1c was measured by high performance liquid chromatography (HPLC) on a VARIANT II analyzer (Bio-Rad laboratories, Montreal, QC, Canada). The recommended threshold HbA1c value of 6.5% did not give the optimal combination of NPV of 0.93 to 0.92 and PPV of 0.40 to 0.61 compared to a threshold HbA1c value of 7.0% that gave an NPV of 0.91 to 0.92, and PPV of 0.61 to 0.73.
The authors concluded that HbA1c is not satisfactory for use as a diagnostic test for diabetes using the threshold values recommended by the Consensus Committee and the International Expert panel due to low positive predictive values. About 12% of individuals with a normal OGTT test will be diagnosed with diabetes using a threshold HbA1c value of 7.0%. This would put considerable burden on health care resources. However, based on the high negative predictive value, HbA1c may be used as a test to rule-out diabetes. The study was published in the December 2011 issue of the journal Clinical Biochemistry.
Related Links:
DynaLIFEDx
Abbott Laboratories
Bio-Rad
Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Capillary Blood Collection Tube
IMPROMINI M3
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more